M&A / Deals Parkinson’s charity partners Biognosys on biomarker project PharmaphorumA new R D project will try to develop assays for LRRK2, a biomarker linked to Parkinson's that has emerged as a major drug target in the disease.M&A / DealsNeuroscienceRead full story pharminent April 15, 2026 Pharmaphorum A new R D project will try to develop assays for LRRK2, a biomarker linked to Parkinson’s that has emerged as a major drug target in the disease. M&A / DealsNeuroscienceRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Daiichi exits OTC, with $1.55bn unit sale to SuntoryNext: Takeda continues to prune partnerships, cuts ties with mRNA-targeting Veritas In Silico Related Stories M&A / Deals Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar pharminent July 10, 2026 M&A / Deals GSK ends dementia alliance with Alector after setbacks pharminent July 9, 2026 M&A / Deals AstraZeneca, GSK intensify China ties with Sino Biopharm deals pharminent July 8, 2026
